Prometheus Biosciences, Inc.
Clinical trials sponsored by Prometheus Biosciences, Inc., explained in plain language.
A biopharmaceutical company developing precision immunology treatments, acquired by Merck.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Can a new infusion drug calm ulcerative colitis?
Disease control CompletedThis trial tests whether tulisokibart, an experimental drug given by IV infusion, can help people with moderate to severe ulcerative colitis achieve remission. About 178 participants will receive either tulisokibart or a placebo for 12 weeks, with the option to continue treatment…
Phase 2 • Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug shows promise for tough Crohn's cases
Disease control CompletedThis study tested a new drug called tulisokibart (PRA023) in 55 people with moderate-to-severe Crohn's disease who had not responded well to other treatments. The main goals were to check safety and see if the drug could improve gut healing and reduce symptoms. After 12 weeks, so…
Phase 2 • Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC